Alzheimer's disease (AD) is the most common neurodegenerative disease in the world. It is
classified as familial and sporadic. The dominant familial or autosomal presentation …

Introduction The overall goal of the Alzheimer's Disease Neuroimaging Initiative (ADNI) is to
validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI is a multisite …

Abstract Characterization of the genetic landscape of Alzheimer's disease (AD) and related
dementias (ADD) provides a unique opportunity for a better understanding of the associated …

Risk for late-onset Alzheimer's disease (LOAD), the most prevalent dementia, is partially
driven by genetics. To identify LOAD risk loci, we performed a large genome-wide …

Background Astrocytes, also called astroglia, maintain homoeostasis of the brain by
providing trophic and metabolic support to neurons. They recycle neurotransmitters …

Highlights•More than 40 loci of interest have been associated with the risk of developing
AD.•Recent genetic data clearly implicate microglia as involved in the pathophysiological …

Background Human genetic association studies point to immune response and lipid
metabolism, in addition to amyloid-beta (Aβ) and tau, as major pathways in Alzheimer's …

Translating human genetic findings (genome-wide association studies [GWAS]) to
pathobiology and therapeutic discovery remains a major challenge for Alzheimer's disease …

Alzheimer's disease (AD) is considered to have a large genetic component. Our knowledge
of this component has progressed over the last 10 years, thanks notably to the advent of …

Lipidomics research could provide insights of pathobiological mechanisms in Alzheimer's
disease. This study explores a battery of plasma lipids that can differentiate Alzheimer's …